Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635795 | 0.85 | TACR1 (0.49) | TACR1DRD4NAAACTSLCTSB | |
| SCHEMBL1768861 | 0.83 | CTSL (0.55) | TACR1SIGMAR1TMEM97NAAACTSL | |
| SCHEMBL4635725 | 0.80 | NAAA (0.50) | TACR1NAAACTSLCTSBCTSK | |
| SCHEMBL5219952 | 0.77 | HRH1 (0.51) | KCNH2 | |
| SCHEMBL4636695 | 0.76 | NAAA (0.53) | TACR1NAAACTSLCTSBCTSK | |
| SCHEMBL4635535 | 0.76 | TACR1 (0.54) | TACR1DRD4SIGMAR1MGLLNAAA | |
| SCHEMBL1769180 | 0.74 | CHRM2 (0.35) | TACR1DRD4POLBHTR2AKCNH2 | |
| SCHEMBL2007270 | 0.72 | OPRM1 (0.47) | HTR2AKCNH2ALDH1A1CYP2D6 | |
| SCHEMBL5982149 | 0.72 | FFAR1 (0.51) | TACR1SIGMAR1S1PR1HTR2AKCNH2 | |
| SCHEMBL6774815 | 0.72 | SLC6A2 (0.42) | KCNH2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617839-B1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RES LTD (GB) | 2008-06-18 | — | — | EP | disclosed |
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | VERNALIS RESEARCH LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1617839-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096209-A1 | THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1049672-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1212054-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-06-12 | — | — | EP | disclosed |
| US-6403574-B1 | TRANQUILIZERS, ANTIEPILEPTIC, MUSCLE RELAXATION PRIOR TO SURGERY | VERNALIS RESEARCH LIMITED (GB) | 2002-06-11 | — | — | US | disclosed |
| WO-2001007023-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049672-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037612-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276452-A1 | Use of azetidinecarboxamide derivatives in therapy | CNR1, CNR2, GPR18 | TACR1 76/4885DRD4 397/4885SIGMAR1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.